Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Encouraging phase I data reported on candidate arthritis immunotherapy

May 8, 2012

SUMMACTA study meets primary endpoint

May 3, 2012

Recruitment complete in phase IIb Synavive trial

May 2, 2012

Ampio completes day 84 analysis of Ampion-In-Knee study

May 2, 2012

Novartis designs novel IL-12RB1-targeted antibodies

May 2, 2012

CrystalGenomics reports on phase IIb CG-100649 trial

April 20, 2012

Eisai divulges new suppressors of prostanoid signaling

April 19, 2012

Another milestone reached in phase IIa Cx-611 study

April 17, 2012

UCB reports on phase III axial spondyloarthritis trial

April 17, 2012

UCB describes new PI3K inhibitors

April 11, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...